AI Generated Image
In U.S., GLP-1 Usage Reaches New High
Gallup News • • business
Key Points:
- The percentage of U.S. adults currently using GLP-1 medications for weight loss rose sharply from 3% in 2024 to 11% in 2026, with 15% reporting lifetime use of these drugs.
- Awareness of GLP-1 weight loss drugs has increased to 91% in 2026, up from 80% in 2024, coinciding with FDA approvals of drugs like Wegovy and Zepbound.
- The U.S. adult obesity rate declined from a peak of 39.9% in 2022 to 36.4% in 2026, inversely tracking with increased GLP-1 usage, while diabetes rates have stabilized after years of increase.
- Brand-name GLP-1 drugs (e.g., Ozempic, Wegovy) account for 68% of current use, but compounded or custom-mixed versions are gaining popularity, partly due to lower costs and insurance coverage issues.
- Users of compounded GLP-1 medications report slightly higher effectiveness and are more likely to have switched from brand-name drugs, indicating a market shift driven by affordability and accessibility.
